Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

INTRODUCTION: Renal cell carcinoma (RCC) represents 2%–3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target o...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonetti, Alessandro, Leonardi, Francesco, Bersanelli, Melissa, Buti, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499780/
https://www.ncbi.nlm.nih.gov/pubmed/28721060
http://dx.doi.org/10.2147/TCRM.S126910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499780/
https://www.ncbi.nlm.nih.gov/pubmed/28721060
http://dx.doi.org/10.2147/TCRM.S126910

Ejemplares similares